Key Takeaways
- KOMO Biosciences has appointed Darryl Sampey, PhD, to its Scientific Advisory Board, bringing over 20 years of biologics development and manufacturing experience.
- Dr. Sampey is co-founder, President, and CEO of BioFactura, a fully integrated biologics development and clinical manufacturing organization he has led since 2004.
- Prior to BioFactura, he held process development and manufacturing roles at Human Genome Sciences, including a key role in commissioning its first cGMP manufacturing facility.
- In his advisory role, Dr. Sampey will provide guidance on platform development, manufacturing strategy, translational execution, and commercialization planning.
- He holds a PhD in Bioengineering and a BS in Chemical Engineering, both from the University of Maryland.
KOMO Biosciences Names Biologics Veteran Darryl Sampey to Advisory Board
KOMO Biosciences has added Darryl Sampey, PhD, to its Scientific Advisory Board, the company announced. Dr. Sampey brings more than two decades of experience in biologics development and manufacturing, with a background spanning cell line and process development, CMC strategy, and complex biopharmaceutical programs.
Background: From Human Genome Sciences to BioFactura
Before establishing his own company, Dr. Sampey worked at Human Genome Sciences, where he led process development and manufacturing teams and contributed to the startup, commissioning, and validation of the firm's first cGMP manufacturing facility and its associated development laboratories.
In 2004, he co-founded BioFactura, where he has served as President and CEO, building the organization into a fully integrated biologics development and clinical manufacturing company.
What the Appointment Means for KOMO Biosciences
“Darryl brings a rare combination of deep technical expertise and real-world experience building and scaling biologics manufacturing capabilities. His perspective will be invaluable as we continue advancing and scaling our precision genomic integration platforms across biomanufacturing and next-generation therapeutic applications,” said Jennifer Manning, CEO of KOMO Biosciences.
As a Scientific Advisory Board member, Dr. Sampey will provide strategic input on platform development, manufacturing scale-up, translational execution, and commercialization planning.
Sampey on the Opportunity
“KOMO's approach to highly efficient, targeted gene integration represents a compelling opportunity to improve control, scalability, timelines, and cost across biomanufacturing and advanced cell engineering applications. I look forward to working with the team as the platform continues to evolve,” said Dr. Sampey.
Dr. Sampey holds a PhD in Bioengineering and a BS in Chemical Engineering, both from the University of Maryland.
